We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Bluebird (BLUE) Up 17.4% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Bluebird Bio (BLUE - Free Report) . Shares have added about 17.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Bluebird due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
bluebird Q1 Earnings and Revenues Beat
bluebird reported a loss of $3.64 per share in first-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of $3.94 but wider than the year-ago quarter's loss of $2.99.
Revenues of $21.8 million easily beat the Zacks Consensus Estimate of $9 million. The figure was up from $12.5 million in the year-ago quarter.
Quarter in Detail
R&D expenses increased to $154.1 million from $122.6 million a year ago due to costs incurred by the company to advance and expand the pipeline.
Selling, general and administrative (SG&A) expenses of $73.2 million were up from $60.3 million in the year-ago quarter to support its operations, overall growth of the pipeline, and commercial-readiness activities.
Pipeline Development
bluebird announced general agreement with the FDA that the clinical data package required to support the BLA submission for LentiGlobin for sickle cell disease (SCD) will be based on data from a portion of patients in the HGB-206 study Group ,who have already been treated. The planned submission will be based on an analysis using complete resolution of severe vaso-occlusive events (VOEs) as the primary endpoint and at least 18 months of follow-up post drug product infusion. Globin response will be used as a key secondary endpoint. The company anticipates additional guidance from the FDA regarding the commercial manufacturing process, including suspension lentiviral vector. The company is planning to seek an accelerated approval and expects to submit the BLA in the second half of 2021.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 48.18% due to these changes.
VGM Scores
Currently, Bluebird has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Bluebird has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Bluebird (BLUE) Up 17.4% Since Last Earnings Report?
A month has gone by since the last earnings report for Bluebird Bio (BLUE - Free Report) . Shares have added about 17.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Bluebird due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
bluebird Q1 Earnings and Revenues Beat
bluebird reported a loss of $3.64 per share in first-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of $3.94 but wider than the year-ago quarter's loss of $2.99.
Revenues of $21.8 million easily beat the Zacks Consensus Estimate of $9 million. The figure was up from $12.5 million in the year-ago quarter.
Quarter in Detail
R&D expenses increased to $154.1 million from $122.6 million a year ago due to costs incurred by the company to advance and expand the pipeline.
Selling, general and administrative (SG&A) expenses of $73.2 million were up from $60.3 million in the year-ago quarter to support its operations, overall growth of the pipeline, and commercial-readiness activities.
Pipeline Development
bluebird announced general agreement with the FDA that the clinical data package required to support the BLA submission for LentiGlobin for sickle cell disease (SCD) will be based on data from a portion of patients in the HGB-206 study Group ,who have already been treated. The planned submission will be based on an analysis using complete resolution of severe vaso-occlusive events (VOEs) as the primary endpoint and at least 18 months of follow-up post drug product infusion. Globin response will be used as a key secondary endpoint. The company anticipates additional guidance from the FDA regarding the commercial manufacturing process, including suspension lentiviral vector. The company is planning to seek an accelerated approval and expects to submit the BLA in the second half of 2021.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 48.18% due to these changes.
VGM Scores
Currently, Bluebird has a poor Growth Score of F, however its Momentum Score is doing a lot better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Bluebird has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.